Article

EZH2 alters aggressive variant prostate cancer subtype evolution, but is not required for neuroendocrine prostate cancer

2025-05-14

Abstract excerpt

Advanced prostate cancer (PrCa) remains a leading cause of cancer-related death among men because nearly all patients progress on standard therapy that targets androgen receptor (AR) signaling. An important mechanism driving therapeutic resistance is lineage plasticity, the ability of PrCa cells to reprogram into lineage variants like neuroendocrine (NE) PrCa that no longer depend on AR signaling. The histone meth...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7e7b262e-e2b9-521f-af6f-d9ae05dab81f
DOI: 10.1101/2025.05.13.653549

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

EZH2 alters aggressive variant prostate cancer subtype evolution, but is not required for neuroendocrine prostate cancerDOI 10.1101/2025.05.13.653549Read

N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancerSemantic proximity Read

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypesSemantic proximity Read

The epigenetic and transcriptional landscape of neuroendocrine prostate cancerSemantic proximity Read

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.Semantic proximity Read

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancerSemantic proximity Read

Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolutionSemantic proximity Read

Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancerSemantic proximity Read

Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancerSemantic proximity Read

Epigenetic remodeling and 3D chromatin reorganization governed by NKX2-1 drive neuroendocrine prostate cancerSemantic proximity Read

EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate CancerSemantic proximity Read

The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancerSemantic proximity Read

PROX1 is an early driver of lineage plasticity in prostate cancerSemantic proximity Read